Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
1(33.3%)
Phase 4
1(33.3%)
Phase 2
1(33.3%)
3Total
Phase 1(1)
Phase 4(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04743791Phase 4Recruiting

Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma

Role: lead

NCT01748175Completed

Implications and Stability of Clinical and Molecular Phenotypes of Severe Asthma

Role: lead

NCT03680976Phase 2Withdrawn

Anti-Inflammatory Lipid Mediators in Asthma

Role: lead

NCT03020810Unknown

Dupilumab Compassionate Use Study

Role: lead

NCT01733485Phase 1Completed

Electrophilic Fatty Acid Derivatives in Asthma

Role: lead

All 5 trials loaded